ROIV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Roivant Sciences Ltd (ROIV) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock has bullish technical indicators and positive analyst sentiment, the company's poor financial performance and insider selling suggest caution. Given the user's impatience and unwillingness to wait for optimal entry points, holding off on buying is recommended until more favorable conditions emerge.
The technical indicators show a bullish trend with MACD above 0 and positively contracting, RSI at 67.614 in the neutral zone, and bullish moving averages (SMA_5 > SMA_20 > SMA_200). The stock is trading near its resistance level (R1: 29.458), which may act as a short-term barrier.
Positive analyst sentiment with multiple firms raising price targets, citing strong potential for brepocitinib and a significant settlement with Moderna. Bullish technical indicators and a history of strong stock performance over the last year (+190%).
Insider selling by Glene Matthew, reducing holdings by over $18 million in recent weeks. Poor financial performance in Q3 2026, with revenue down -77.83% YoY and net income down -256.98% YoY. No recent congress trading data or significant hedge fund activity.
The company's Q3 2026 financials show a significant decline in revenue (-77.83% YoY), net income (-256.98% YoY), and EPS (-265.22% YoY). Gross margin also dropped to 64.98, down -33.10% YoY, indicating a challenging financial environment.
Analysts are bullish on the stock, with multiple firms maintaining Buy or Overweight ratings and raising price targets to a range of $29-$40. Positive sentiment is driven by strong potential for brepocitinib and the resolution of the Moderna settlement.
